Epilepsy in children with lymphoproliferative syndrome
https://doi.org/10.17749/2077-8333.2018.10.2.083-094
Abstract
There are considerable variations in the reported incidence of early and late epilepsy in children with lymphoproliferative diseases. The etiology of seizures in pediatric patients with hemoblastosis during polychemotherapy can be diverse: dysmetabolic, infectious, toxic, ischemic, posthemorrhagic. The treatment strategy selected by the neurologist largely depends on the causes of the paroxysmal conditions. When choosing the anti-seizure therapy one should consider the course of hemoblastoses and the possible effects of polychemotherapy. The article presents pediatric cases and the analysis of acute lymphoblastic leukemia with developing epileptic seizures.
About the Authors
I. O. SchederkinaRussian Federation
1/9 Dobryninskiy 4-y per., Moscow 119049, Russia
MD, PhD, Neurologist, Head of the Center for the Treatment of Cerebrovascular Diseases in Children and Adolescents, Morozov Children’s Clinical Hospital
O. A. Tiganova
Russian Federation
1/9 Dobryninskiy 4-y per., Moscow 119049, Russia
1 Ostrovityanova Str., Moscow 117997, Russia
MD, PhD, Chief External Oncologist at the Moscow City Department of Healthcare; Hematologist- oncologist, Morozov Children’s Clinical Hospital; Associate Professor at the Department of Pediatrics, N. I. Pirogov Russian National Research Medical University. Tel.: +7 (499) 236-24-02
I. E. Koltunov
Russian Federation
1/9 Dobryninskiy 4-y per., Moscow 119049, Russia
MD, Honored Medical Doctor of Russia, Professor, Chief Physician, Morozov Children’s Clinical Hospital. Tel.: +7 (499) 236-24-02
N. V. Natrusova
Russian Federation
1/9 Dobryninskiy 4-y per., Moscow 119049, Russia
MD, Neurologist, Morozov Children’s Clinical Hospital. Tel.: +7 (495) 959-88-00
K. L. Kondratchik
Russian Federation
1/9 Dobryninskiy 4-y per., Moscow 119049, Russia
MD, PhD, Head of the Center for Pediatric Oncology and Hematology, Head of the Department of Oncology and Hematology, Morozov Children’s Clinical Hospital, Associate Professor at the Department of Oncology, Hematology and Immunology, N. I. Pirogov Russian National Research Medical University. Tel.: +7 (499) 236-24-02
References
1. Kaprin A. D., Starinskij V. V., Petrov G. V. Malignant neoplasms in Russia in 2015 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’) (in Russian)]. Moscow. 2017; 250 s.
2. Kuznecova E. I., Gorbachevskaya N. L. Onkopediatriya. 2017; 4 (1): 74-81. DOI: 10.15690/onco.v4i1.1687.
3. Rumyancev A. G., Maschan A. A., Rumyanceva Yu.V., Karachunskij A. I. Federal clinical guidelines for the diagnosis and treatment of acute lymphoblastic leukemia in children and adolescents [Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu ostrogo limfoblastnogo lejkoza u detej i podrostkov (in Russian)]. Moscow. 2015. 71 s.
4. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Ed. prof. I. V. Poddubnoy, prof. V. G. Savchenko [Roscijskie klinicheskie rekomendacii po diagnostike i lecheniyu limfoproliferativnyh zabolevanij. Pod rukovodstvom prof. I. V. Poddubnoj, prof. V. G. Savchenko (in Russian)]. Moscow. 2013; 104 s.
5. Rumyancev A. G. Maschan A. A., Samochatova E. V. Accompanying therapy and infection control in hematological and oncological diseases [Soprovoditel’naya terapiya i kontrol’ infekcij pri gematologicheskih i onkologicheskih zabolevaniyah (in Russian)]. Moscow. 2006. 447 s.
6. Bhojwani D., Sabin N. D. et all. Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2014; 32 (9): 949-959.
7. Forster V. J., Frederik W. van Delft, Baird S. F., Mair S., Skinner R., Halsey Ch. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol. 2016; 78: 1093-1096. DOI 10.1007/s00280-016-3153-0.
8. Flott-Rahmel B. et al. Eur J Pediatr. 1998; 157: 112-7.
9. Aboian M. S., Junna Mi.R., Krecke K. N., Wirrell E. C. Mesial Temporal Sclerosis After Posterior Reversible Encephalopathy Syndrome. Pediatric Neurology. 2009; 41 (3): 226-228.
10. Fasano R. E., Bergen D. C. Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia. Seizure. 2009; 18 (4): 298-302.
11. Rubinstein L. J., Herman M. M., Long T. F., Wilbur J. R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975 Feb; 35 (2): 291-305.
12. Slater L. M., Wainer R. A., Serpick A. A. Vincristine neurotoxicity with hyponatremia. Cancer. 1969; 23: 122-5.
13. Harnicar S., Adel N., Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009; 15: 175-82.
14. Jeng M., Feusner J. Severe vincristine toxicity potentiated by itraconazole therapy in a child with acute lymphocytic leukemia. J Pediatr Hematol Oncol. 1999; 21: 329-330.
15. Mahapatra M., Kumar R., Choudhry V. P. Seizures as an adverse drug reaction after therapeutic dose of vincristine. Ann Hematol. 2007; 86: 153-4.
16. Bermúdez M., Fuster J. L., Llinares E., Galera A., Gonzalez C. Itraconazole- related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol. 2005; 27: 389-92.
Review
For citations:
Schederkina I.O., Tiganova O.A., Koltunov I.E., Natrusova N.V., Kondratchik K.L. Epilepsy in children with lymphoproliferative syndrome. Epilepsy and paroxysmal conditions. 2018;10(2):82-94. (In Russ.) https://doi.org/10.17749/2077-8333.2018.10.2.083-094
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.